Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

Published: September 2018

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0182-9DOI Listing

Publication Analysis

Top Keywords

safety nintedanib
4
nintedanib treatment
4
treatment fibrotic
4
fibrotic lung
4
lung disease
4
disease allogeneic
4
allogeneic hematopoietic
4
hematopoietic stem
4
stem cell
4
cell transplantation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!